Short-term safety of dual versus single antiplatelet therapy in flow diversion for distal intracranial aneurysms: results from the DART trial
- 21 October 2025
- journal article
- Published by BMJ in Journal of NeuroInterventional Surgery
- Vol. 18 (10) , 2045-2050
Abstract
Background and purpose: Flow diverters (FDs) have become one of the primary treatments for intracranial aneurysms (IAs). However, their use in distal IA has been associated with higher complication rates compared with other techniques. The development of coated FDs, in combination with novel antiplatelet regimens, offers promising strategies to improve the safety profile of FDs in this context. This trial aimed to compare mono antiplatelet therapy (MAPT) using prasugrel versus dual antiplatelet therapy (DAPT) with aspirin and prasugrel for the treatment of distal IA using the p48 MW HPC FD (WallabyPhenox). Methods: This was a multicenter, prospective, parallel-group, single-blind, non-inferiority randomized trial. Between February 2021 and February 2025, 140 patients were enrolled. After excluding 11 patients, 129 were included in the final analysis. The primary endpoint was the absence of new neurological deficits, defined as no shift in the modified Rankin Scale (mRS) score. The secondary endpoint was the incidence of any stroke. Results: At the 30-day follow-up, 66 patients (98.5%) in the MAPT group and 59 patients (95.2%) in the DAPT group showed no new neurological deficits. With a predefined non-inferiority margin of 5%, the difference of 3.35% confirmed the non-inferiority of MAPT compared with DAPT (p=0.002). The incidence of any stroke was 4/67 (5.9%) in the MAPT group and 6/62 (9.6%) in the DAPT group (p=0.431). Conclusion: Prasugrel monotherapy for the treatment of distal IAs using the p48 MW HPC was non-inferior to DAPT within the first 30 days following treatment. Clinical trial registration: https://ensaiosclinicos.gov.br/rg/RBR-3q9zb73. UTN code: U1111-1290-2489. Research Ethics Committee of the Hospital das Clínicas de Ribeirão Preto - Universidade de São Paulo. CAAE number: 29848720.0.1001.5440.Keywords
Funding Information
- wallaby-phenox (N/A)
This publication has 19 references indexed in Scilit:
- Two year follow-up of distal unruptured intracranial aneurysms treated with a surface modified flow diverter under prasugrel monotherapyJournal of NeuroInterventional Surgery, 2023
- Use of a p64 MW Flow Diverter with Hydrophilic Polymer Coating (HPC) and Prasugrel Single Antiplatelet Therapy for the Treatment of Unruptured Anterior Circulation Aneurysms: Safety Data and Short-term Occlusion RatesCardioVascular and Interventional Radiology, 2022
- Treatment of distal unruptured intracranial aneurysms using a surface-modified flow diverter under prasugrel monotherapy: a pilot safety trialJournal of NeuroInterventional Surgery, 2021
- Distal anterior cerebral artery aneurysms treated with flow diversion: experience of a large-volume center and systematic review of the literatureJournal of NeuroInterventional Surgery, 2020
- The p48 Flow Modulation Device with Hydrophilic Polymer Coating (HPC) for the Treatment of Acutely Ruptured Aneurysms: Early Clinical Experience Using Single Antiplatelet TherapyCardioVascular and Interventional Radiology, 2020
- The p48_HPC antithrombogenic flow diverter: initial human experience using single antiplatelet therapyJournal of International Medical Research, 2019
- Anti-thrombogenic coatings for devices in neurointerventional surgery: Case report and review of the literatureInterventional Neuroradiology, 2019
- Aggregometry Response to Half-dose Prasugrel in Flow-diverting Stent ImplantationClinical Neuroradiology, 2019
- Hydrophilic Stent Coating Inhibits Platelet Adhesion on Stent Surfaces: Initial Results In VitroCardioVascular and Interventional Radiology, 2018
- Flow diversion with the pipeline embolization device for patients with intracranial aneurysms and antiplatelet therapy: A systematic literature reviewClinical Neurology and Neurosurgery, 2017